Endocrine Abstracts

Objectives: To date, there has been no population-wide data looking at the adherence to published TUS reporting guidelines for thyroid nodule malignancy risk assessment. In our health care region in 2018, two radiology groups worked closely with endocrinologists to improve the quality of their TUS reports by adhering to the 2015 ATA or the 2017 TIRADS guidelines. We aim to present the improvement in TUS reports quality with these dedicated changes.Method...

Introduction: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have RAI-resistant disease, resulting in poor prognosis and high disease-related mortality. Current studies of individualized therapy with different MAPK inhibitors report restoring RAI-avidity in 50 – 70% of BRAF and RAS mutated and thyroid cancers with no detected driver mutation. Five recent case reports of rare NTRK and RET-PTC fusion-positive metast...

Objective: The 2016 ATA RR assessment recommendations for patients with DTC were based on retrospective studies. We present the first outcomes of a prospective assessment of thyroid cancer management according to the ATA RR stratification.Methods: Using the Calgary prospective thyroid cancer database, we identified 612 patients with differentiated thyroid cancer (DTC) treated at our centre between April 2017 and December 2021. Each case was reviewed by t...